LY9 anticorps (AA 160-360)

N° du produit ABIN7171457

Détail du produit anti-LY9 anticorps

Antigène: LY9 (CD229) (Lymphocyte Antigen 9 (CD229))

Épitope: AA 160-360

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp LY9 est non-conjugé

Application: Immunohistochemistry (IHC), ELISA

Réactivité croisée: Humain

Purification: Antigen Affinity Purified

Immunogène: Recombinant Human T-lymphocyte surface antigen Ly-9 protein (160-360AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: IHC:1:20-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur LY9

Antigène: LY9 (CD229) (Lymphocyte Antigen 9 (CD229))

Autre désignation: LY9 (CD229 Produits)

Synonymes: anticorps LY9, anticorps CD229, anticorps SLAMF3, anticorps hly9, anticorps mLY9, anticorps AI893573, anticorps Lgp100, anticorps Ly-9, anticorps T100, anticorps lymphocyte antigen 9, anticorps LY9, anticorps Ly9

Sujet:

Background: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion, the costimulatory activity requires SH2D1A (PubMed:22184727). Promotes recruitment of RORC to the IL-17 promoter (PubMed:22989874). May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4(+) T-cells. May negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells (By similarity).

Aliases: CD229 antibody, Cell surface molecule Ly-9 antibody, Cell surface molecule Ly9 antibody, hly9 antibody, LY 9 antibody, Ly9 antibody, LY9_HUMAN antibody, Lymphocyte antigen 9 antibody, mLY9 antibody, Signaling lymphocytic activation molecule 3 antibody, SLAM family member 3 antibody, SLAMF3 antibody, T lymphocyte surface antigen Ly9 precursor antibody, T-lymphocyte surface antigen Ly-9 antibody

UniProt: Q9HBG7

Pathways: BCR Signaling